Business ❯ Pharmaceutical Industry

Drug Pricing

Market Competition Market Access Market Trends Market Dynamics Market Regulation Market Strategies Market Launch Insurance Coverage Market Impact Generic Medications Novo Nordisk Market Demand Generic Drugs Market Strategy Negotiations Healthcare Costs Consumer Health Direct-to-Consumer Sales Wegovy Government Regulation Weight Loss Medications Corporate Agreements Weight Loss Drugs Investment Cost Reduction Strategies Insurance Companies Lobbying Consumer Access Pharmacy Benefit Managers Eli Lilly Tariffs Gilead Sciences Fertility Medications Mark Cuban Generic Medicines Market Availability Obesity Treatments GLP-1 Medications Pfizer Aduhelm Market Negotiations Black Market Generic Production Monopolist Costco Agreements Reimbursement Structure Profitability Regulatory Approval Market Regulations Cost-Effectiveness Insurance Negotiations Health Economics State Importation Programs Brand-name Drugs Specific Drugs Cost Reduction Import Costs Turing Pharmaceuticals Partnerships Healthcare Policy Insurance Costs Healthcare Agreements Medicare Negotiation Program Ozempic Pricing Ozempic Consumer Discounts Government Regulations CVS Price Negotiation Legislation Impact Counterfeit Drugs Market Cost of Treatment Production Costs CVS Health Negotiation Processes Casgevy Cost Medicaid Retail Pharmacy Medicare Reimbursement Pricing Strategy Investment Strategies Insurance Semaglutide Costs Government Policies Access to Medicines Regeneron Patent Expiration Opill Retail Price Aduhelm Pricing Rebate Programs Tariff Implications Medicare Drug Price Negotiation Program Oncology Market Monopoly Market Analysis Corporate Actions Health Advocacy Patient Support Programs Market Reactions Pfizer Agreements

FDA Proposes Blocking Bulk Compounding of GLP-1 Drugs by Outsourcing Facilities

The move signals the agency sees no clinical need for bulk versions given improved supply.

FDA Approves First Gene Therapy for Inherited Hearing Loss

Trump Seals Regeneron Drug-Pricing Pact, Completing 17-Company Push

Dosing Disputes, Counterfeits, and a Patent Wall Put Keytruda Under Fresh Scrutiny

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

Amazon Pharmacy Adds FDA-Approved Wegovy Pill With $25 Copays and Nationwide Delivery

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

CMS Chief Mehmet Oz Urges ‘Trump Babies’ Before 2026 at Oval Office Drug-Pricing Event

TrumpRx–Pfizer Drug-Price Deal Leaves Key Details Unclear

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide

Bristol Myers Sets U.K. Price for New Schizophrenia Drug Equal to U.S., Threatens to Pull Product

Wegovy Wins FDA Nod for MASH as Novo Rolls Out $499 Cash Ozempic in U.S.

FDA Approves Yeztugo, Twice-Yearly HIV Prevention Injection

FDA Approves Twice-Yearly Lenacapavir Injection for HIV Prevention

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves